Matinas BioPharma Q2 net loss $5.7M ($0.02/sh); signs non-binding MAT2203 term sheet

Matinas BioPharma Holdings, Inc.

2024-Q2 EPS reported -$0.05 vs consensus -$1.27 ▲ beat (+96.1%)

Net loss for Q2 2024 was $5.7 million ($0.02 per share), compared to $6.1 million ($0.03) in Q2 2023.
Cash, cash equivalents and marketable securities were $14.3 million as of June 30, 2024; raised $10M in April offering.
Signed non-binding term sheet for global licensing rights to develop and commercialize oral MAT2203 for invasive aspergillosis.
31 patients enrolled in MAT2203 Compassionate/Expanded Use Access Program; 7 additional under evaluation.
LNC platform showed tumor inhibition in animal models; additional optimization needed before selecting product candidate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.